Sign in

    Julian Harrison

    Senior Research Analyst at H.C. Wainwright & Co.

    Julian Harrison is a Senior Research Analyst at H.C. Wainwright & Co., specializing in coverage of biopharmaceutical and life sciences companies. He has provided research and recommendations for firms such as Phio Pharmaceuticals and Theravance Biopharma, with recent coverage including Avalo Therapeutics and Rezolute, Inc., consistently delivering buy ratings and maintaining strong buy recommendations across several quarters. His analyst performance includes active participation in earnings calls and maintaining coverage on select emerging healthcare firms, but quantified metrics such as TipRanks rankings and average returns are not publicly available. Harrison’s career timeline and credentials, including securities licenses or FINRA registrations, are not fully detailed in publicly accessible profiles, and specific job start dates or previous employers remain undisclosed.

    Julian Harrison's questions to Phio Pharmaceuticals (PHIO) leadership

    Julian Harrison's questions to Phio Pharmaceuticals (PHIO) leadership • Q2 2018

    Question

    Julian Harrison of H.C. Wainwright & Co. inquired about the timeline for IND-enabling studies for the candidate under collaboration with Iovance and sought clarification on the status of out-licensing efforts for RXI-109 and Samcyprone.

    Answer

    Chief Development Officer Gerrit Dispersyn explained that the most direct path to the clinic is through investigator-initiated INDs with expert centers like CCIT. President and CEO Geert Cauwenbergh clarified that out-licensing efforts are ongoing, with due diligence underway with approximately a dozen companies for the dermatology and ophthalmology assets combined.

    Ask Fintool Equity Research AI